Approval · Notice of Compliance 14146 · 2013
ORENCIA: Notice of Compliance 14146
Issued February 21, 2013
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 14146
- Date
- February 21, 2013
- Company
- Bristol-Myers Squibb CanadaSt-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New formulation for subcutaneous administration
- Therapeutic class
- Selective co-stimulation modulator
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ORENCIA | 02402475 | Marketed |
Medicinal ingredients
- ABATACEPT 125 MG per ML